Capsovision, Inc (CV) — SEC Filings
Capsovision, Inc (CV) — 17 SEC filings. Latest: EFFECT (Apr 23, 2026). Includes 7 8-K, 3 S-1/A, 2 4.
View Capsovision, Inc on SEC EDGAR
Overview
Capsovision, Inc (CV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 23, 2026: CapsoVision, Inc. filed an EFFECT form with the SEC on April 23, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-001300, relates to Act 33 and File No. 333-295153. The company's business address is 18805 Cox Avenue, Suite 250, Saratoga,
Sentiment Summary
Across 17 filings, the sentiment breakdown is: 2 bearish, 15 neutral. The dominant filing sentiment for Capsovision, Inc is neutral.
Filing Type Overview
Capsovision, Inc (CV) has filed 1 3, 2 4, 1 EFFECT, 7 8-K, 2 10-Q, 3 S-1/A, 1 S-1 with the SEC between May 2025 to Apr 2026.
Filings by Year
Recent SEC Filings (17)
Risk Profile
Risk Assessment: Of CV's 13 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $9,636,000 |
| Net Income | -$17,921,000 |
| EPS | N/A |
| Debt-to-Equity | 0.25 |
| Cash Position | $17,787,000 |
| Operating Margin | -187.6% |
| Total Assets | $25,661,000 |
| Total Debt | $5,219,000 |
Key Executives
- HARARI ELIYAHOU ET AL
- Kang-Huai (Johnny) Wang
- Portia Ku, Esq.
- Kurt Berney, Esq.
- Richard I. Anslow
- Jonathan Deblinger
- Joseph A. Smith
- Portia Ku
- Kurt Berney
Industry Context
The medical device industry, particularly in areas like gastrointestinal diagnostics, is characterized by significant R&D investment, long product development cycles, and stringent regulatory hurdles. Companies like CapsoVision compete on technological innovation, clinical efficacy, and market adoption, often requiring substantial capital to fund growth and navigate regulatory pathways.
Top Tags
IPO (5) · Medical Technology (4) · insider-filing (3) · S-1/A (3) · Electromedical Devices (3) · Emerging Growth Company (3) · SEC Filing (3) · registration-statement (2) · ownership-change (2) · form-4 (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Acceptance Date | 2026-04-23 | Indicates when the SEC officially accepted the filing. |
| Effectiveness Date | 2026-04-22 | Marks the date the registration statement became effective. |
| Net Loss | $17.921M | for the nine months ended September 30, 2025, increased from $15.259M in 2024 |
| Net Revenue | $9.636M | for the nine months ended September 30, 2025, up from $8.304M in 2024 |
| Net Cash Used in Operating Activities | $15.178M | for the nine months ended September 30, 2025, indicating significant cash burn |
| Net Proceeds from IPO | $23.37M | received on July 3, 2025, boosting cash reserves |
| Cash and Cash Equivalents | $17.787M | as of September 30, 2025, up from $9.319M at December 31, 2024 |
| Research and Development Expenses | $12.589M | for the nine months ended September 30, 2025, increased from $12.004M in 2024 |
| General and Administrative Expenses | $5.101M | for the nine months ended September 30, 2025, increased from $2.754M in 2024 |
| Common Stock Shares Outstanding | 46,843,225 | as of November 11, 2025, significantly increased post-IPO |
| SEC File Number | 001-42705 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification Number | 20-3369494 | Unique identifier for tax purposes. |
| Cash Balance | $1.066M | Significantly down from $9.319M at Dec 31, 2024, highlighting liquidity issues. |
| IPO Gross Proceeds | $28.1M | Raised in July 2025, but deemed insufficient by management for future operations. |
| Stockholders' Deficit | $138.986M | Increased from $129.510M at Dec 31, 2024, reflecting accumulated losses. |
Frequently Asked Questions
What are the latest SEC filings for Capsovision, Inc (CV)?
Capsovision, Inc has 17 recent SEC filings from May 2025 to Apr 2026, including 7 8-K, 3 S-1/A, 2 4. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CV filings?
Across 17 filings, the sentiment breakdown is: 2 bearish, 15 neutral. The dominant sentiment is neutral.
Where can I find Capsovision, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Capsovision, Inc (CV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Capsovision, Inc?
Key financial highlights from Capsovision, Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CV?
The investment thesis for CV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Capsovision, Inc?
Key executives identified across Capsovision, Inc's filings include HARARI ELIYAHOU ET AL, Kang-Huai (Johnny) Wang, Portia Ku, Esq., Kurt Berney, Esq., Richard I. Anslow and 4 others.
What are the main risk factors for Capsovision, Inc stock?
Of CV's 13 assessed filings, 2 were flagged high-risk, 8 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Capsovision, Inc?
Forward guidance and predictions for Capsovision, Inc are extracted from SEC filings as they are enriched.